Open AccessThe Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Author(s) -
David P. Durham,
Laura Skrip,
R. Douglas Bruce,
Sílvia Vilarinho,
Elamin H. Elbasha,
Alison P. Galvani,
Jeffrey P. Townsend
Publication year - 2015
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/civ894
Subject(s) - medicine , hepatitis c virus , hepatitis c , virology , chronic hepatitis , interferon , hepatitis a virus , hepatitis , virus , intensive care medicine
The effectiveness of interferon-free direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screening and treatment rates, particularly among people who inject drugs (PWIDs).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom